At-risk people diagnosed with COVID-19 across the United States and Canada can participate in the testing of a common antidepressant.
None of 80 outpatients who received fluvoxamine in a clinical trial became seriously ill after 15 days.
Our Alban Gaultier, PhD, found last year that the drug can reduce the production of cytokines, which flood the body when the immune system spirals out of control.
The discovery could have implications for autism and neurodegenerative diseases such as Alzheimer's.
UPDATE: The University of Michigan came out on top with a potential treatment for tinnitus. Congrats to them and to the Kipnis team for a great performance!
Now we may know why specific brain cells die in Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
